Transaction · 0002150331-26-000002

Aguirre Jarrad Mattieu

Aguirre Jarrad Mattieu, CMO, reported a transaction classified as grant at Lyell Immunopharma, Inc. involving 47500.000000 shares for an estimated $0.00. Reported holdings after the transaction were 47500.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACMO
LYELLyell Immunopharma, Inc.
Trade date
Sep 10, 2026
Filing date
Sep 10, 2026
View on SEC Insider profile
Disclosed value$0Shares × reported price
Shares traded47.5k$0.00 per share
Holdings after47.5kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

LYEL price since this filing

Daily closing prices, with the filing date and available return windows
LYEL · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -3.7%1w ago +0.0%1d ago +0.0%
Returns since7d -30.1%30d -43.6%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0002150331-26-000002
Option (right to buy)
Transaction date
Sep 10, 2026
Filed Sep 10, 2026, 11:31 PM · 0d delay
Shares
47,500 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
47,500 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership Large Holdings Increase
Filing-only score

-6 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 0

    Filing reported within two business days of the transaction.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Medical Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Includes 14,451 restricted stock units ("RSUs") under the Issuer's 2021 Equity Incentive Plan that are subject to time-based vesting and will be settled in common stock subject to vesting as follows:…

  2. F2

    12.5% of the option shares will vest on February 28, 2027, with the remaining option shares to vest in equal monthly installments over the following 42 months, subject to the reporting person providin…

Original filing · 0002150331-26-000002
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

LYEL